Valuation: CombiGene AB

Market Cap 45.34M 4.66M 4.09M 3.77M 3.49M 6.61M 446M 6.74M 17.62M 218M 17.49M 17.11M 758M P/E 2024
-1.05x
P/E 2025 -3.62x
Enterprise Value 39.5M 4.06M 3.56M 3.29M 3.04M 5.76M 389M 5.87M 15.35M 190M 15.24M 14.9M 660M EV / Sales 2024
-13.3x
EV / Sales 2025 128x
Free-Float
44.24%
Yield 2024
8.4%
Yield 2025 88.5%
1 day+3.93%
1 week+3.03%
Current month+5.78%
1 month+7.69%
3 months+10.19%
6 months+2.15%
Current year+5.31%
1 week 2.19
Extreme 2.19
2.38
1 month 2.05
Extreme 2.05
2.4
Current year 1.75
Extreme 1.75
2.6
1 year 1.75
Extreme 1.75
2.87
3 years 1.27
Extreme 1.27
7.4
5 years 1.27
Extreme 1.27
20.05
10 years 1.27
Extreme 1.27
147
Manager TitleAgeSince
Chief Executive Officer 48 30/07/2025
Director TitleAgeSince
Director/Board Member 54 09/12/2024
Chairman - 31/12/2024
Change 5-day change 1-year change 3-year change Capi.($)
+3.93%+3.03%-0.83%-65.90% 4.66M
+0.53%-2.50%+73.03%+128.84% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+1.03%+4.61%+21.01%+472.25% 25.26B
+0.57%-3.33%-15.64%-12.22% 23.65B
+3.93%+3.35%+43.09%-2.47% 18.69B
+1.63%+2.72%+40.36%-24.66% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-0.92%+1.58%+35.79% - 14.26B
+1.05%+1.24%+28.30%+196.49% 14.1B
Average +1.18%+3.70%+51.31%+128.50% 23.94B
Weighted average by Cap. +0.40%+2.20%+58.38%+143.22%

Financials

2024 2025
Net sales 2M 205K 180K 166K 154K 291K 19.66M 297K 777K 9.62M 771K 754K 33.41M 304K 31.23K 27.39K 25.29K 23.37K 44.29K 2.99M 45.18K 118K 1.46M 117K 115K 5.08M
Net income -44.88M -4.61M -4.04M -3.73M -3.45M -6.54M -441M -6.67M -17.44M -216M -17.31M -16.93M -750M -12.36M -1.27M -1.11M -1.03M -950K -1.8M -122M -1.84M -4.8M -59.49M -4.77M -4.66M -207M
Net Debt -73.75M -7.58M -6.64M -6.13M -5.67M -10.74M -725M -10.96M -28.65M -355M -28.45M -27.83M -1.23B -5.84M -600K -526K -486K -449K -851K -57.46M -868K -2.27M -28.12M -2.25M -2.2M -97.62M
Logo CombiGene AB
Larkberget AB, formerly Combigene AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Employees
5
Date Price Change Volume
09/07/26 SEK 2.380 +3.93% 110
08/07/26 SEK 2.290 +1.78% 14,400
07/07/26 SEK 2.250 +0.90% 5,976
06/07/26 SEK 2.230 -0.45% 2,951
03/07/26 SEK 2.240 -3.03% 920
  1. Stock Market
  2. Stocks
  3. LARK Stock